# US 10,502,731 B2 · Use of anoctamin as a biomarker for radiation biodosimetry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,502,731 B2
- Document ID: US10502731B2
- Status: Granted
- Kind: B2
- Application number: 15/822,923
- Filed: 2017-11-27
- Published: 2018-03-15
- Granted: 2019-12-10
- Earliest claimed: 2012-10-05
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Sadasivan Vidyasagar; Paul Okunieff
- Web page: https://patentgrep.com/patent/US10502731B2

## CPC

- G01N 33/54306: {Solid-phase reaction mechanisms}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2500/10: involving cells
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In one embodiment, the present invention pertains to the use of anoctamin as a biomarker for determining radiation dosimetery. In certain embodiments, the present invention relates to the use of anoctamin as a biomarker for diagnosing the presence of radiation toxicity in a subject who has been exposed to ionizing radiation, as well as for determining the absorbed radiation dose in a subject who has been exposed to a known or unknown dose of ionizing radiation. In another embodiment, the expression level of anoctamin can be used as a secondary endpoint to determine mechanisms of action and/or pharmacodynamic (PD) effects of an agent for reducing radiation toxicity.

## Claims

### Claim 1

A method of mitigating radiation toxicity in a human subject, who has undergone therapy with ionizing radiation, wherein the method comprises:
(a) providing a blood sample from a subject who has been subjected to therapy with a predetermined dose of ionizing radiation;
(b) determining anoctamin 1 expression level in the subject's blood sample; and
(c) comparing the expression level determined in step (b) to a level of anoctamin 1 expression in the subject prior to the subject receiving the radiation therapy;
wherein if the level of anoctamin 1 expression determined in (b) is greater than 105% of the anoctamin 1 expression level of the subject before the subject received the predetermined dose of ionizing radiation, then prescribing additional radiation at a dose lower than the predetermined dose or discontinuing radiation therapy; and
if the level of anoctamin 1 expression determined in (b) is no greater than 105% of the anoctamin 1 expression level of the subject before the subject received the predetermined dose of ionizing radiation, then continuing the radiation therapy at the predetermined dose.